Oddo BHF - AstraZeneca PLC (AZN) AstraZeneca : Les investigations en Chine continuent de peser sur le titre

Report

Oddo BHF

Damien Choplain ...

Martial Descoutures

AstraZeneca : Les investigations en Chine continuent de peser sur le titre

>Les faits - La semaine dernière, nous avons appris que le président Chine d'AZN coopérait avec les autorités locales dans le cadre d’une enquête en cours et plus récemment, Bloomberg a publié un article avec des détails supplémentaires. Selon les articles de presse, l'enquête porte sur « des tactiques de vente agressives utilisées pour au moins deux de ses médicaments oncologiques, le traitement du cancer du poumon Tagrisso et l'immunothérapie Imjud ».Les médias...

06/11/2024 1 FR

Underlying

AstraZeneca PLC

AstraZeneca is a holding company. Through its subsidiaries, Co. operates as a biopharmaceutical company engaged in discovering, developing, manufacturing and commercializing its pipeline of small molecule and biologic prescription medicines, including targeted business development through collaboration, in-licensing and acquisitions. Co. is focused on three main therapy areas: Oncology, Cardiovascular and Metabolic Diseases, and Respiratory. Co. is also selectively active in autoimmunity, infection and neuroscience. In addition, Co. works across small molecules, oligonucleotides and other drug platforms, as well as biologic medicines.

See profile

GB0009895292 London Stock Exchange United Kingdom

Provider

Oddo BHF

Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

See profile

Analysts

Damien Choplain

Martial Descoutures

Other Reports on these Companies

New Street Research

Obesity Thematic - A Deep-Dive into Amylin

In the coming days at Obesity Week, we will see multiple datasets from amylin assets that could help to further support our belief that amylin combinations could become a material MOA in the Obesity market. Ahead of the Cagrisema P3 readout, we dig deep into the potential for amylin and show: 1) It has a superior tolerability profile, 2) Could preserve lean muscle mass and 3) Could be neuroprotective. We analyse the majority of the clinical data available on these drugs & show that the full promise of this class is yet to be fully appreciated. For access to the full note, please contact Naresh...

November 1, 2024 November 1, 2024 1 EN

Oddo BHF

ODDO : Feedback from the MS Expert Access event: still many areas for improvement

Last week, we organised an Expert Access event on multiple sclerosis (MS) with the participation of Dr Géraldine Androdias, a neurologist at Lyon University Hospital. Dr Androdias presented the key points of the ECTRIMS 2024 conference, as well as new trends in treating the illness. We note an unmet need in the primary progressive and secondary progressive forms, a real interest for the BTKi class with the greater penetration of the blood-brain barrier, and expectations for the a...

October 23, 2024 October 23, 2024 1 EN

BMW : Weak Q3 Auto results below expectations; pace of recovery will be key

>Q3 even weaker than feared on supply chain/China - BMW reported Q3 results that came below expectations (Autos EBIT -16% below consensus).Q3 revenues came in at € 32.4bn, -16% y-o-y, -12% q-o-q, slightly below expectations (company-compiled css at € 33.3bn, ODDO BHF€ 32.8bn) with adj. EBIT at € 1.7bn, -61% y-o-y, -56% q-o-q implying a margin of 5.2%, -600 bps y-o-y, below estimates (css at 5.0%, ODDO BHF 5.6%).Looking at individual business units, Autos ...

1h / 39m 1h / 39m 1 EN

Anthony Dick ... (+2)

Anthony Dick
Michael Foundoukidis

BMW : Weak Q3 Auto results below expectations; pace of recovery will be key

1h / 41m 1h / 41m 1 FR

Olfa Taamallah ... (+2)

Olfa Taamallah
Yan Derocles

Hensoldt AG : Disappointing Q3 due to a negative product mix on sensors

>Sensors penalises Q3 performance (adjusted EBITDA 7% below css) - Q3 2024 ended up below expectations in terms of adjusted EBITDA (7% below css), with lower profitability in sensors offsetting a welcome recovery in optronics. Adjusted EBITDA was up 22% to € 84m (ODDO BHF: € 93.4m; company-compiled css: € 90.4m) for revenues up 28.8% to € 528m, leading to a margin of 19.5% (+81bp) excluding pass-through. The disappointment mainly comes from the sensors business, for ...

1h / 44m 1h / 44m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

AstraZeneca : Les investigations en Chine continuent de peser sur le titre

Obesity Thematic - A Deep-Dive into Amylin

ODDO : Feedback from the MS Expert Access event: still many areas for improvement

BMW : Weak Q3 Auto results below expectations; pace of recovery will be key

BMW : Weak Q3 Auto results below expectations; pace of recovery will be key

Hensoldt AG : Disappointing Q3 due to a negative product mix on sensors

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe